[PDF] Top 20 Triple-negative breast cancer: new perspectives for targeted therapies

... limited binding affinity for other vascular endothelial growth factor-receptor (VEGFR) ligands, VEGF-B, and VEGF-C. Newer antiangiogenic agents bind to VEGFR-2 and thus prevent all ligand binding to this target. ... See full document

... Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify molecular-based ...21 breast cancer data sets and ... See full document

... TNBC. Cancer growth stimulatory signals are represented by red ar- rows and inhibitory interventions by green arrows and break ...Likewise cancer growth stimulatory proteins are shown in red and yellow, ... See full document

... Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype associated with frequent recurrence and ...targeted therapies. Androgen signaling is necessary for normal ... See full document

... Abstract: Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen ... See full document

... Breast cancer continues to be the second leading cause of cancer-related deaths among women ...of breast cancers are estrogen recep- tor a-positive (ERa + ) and progesterone receptor-positive ... See full document

... Breast cancer is one of the most widespread carcinoma and one of the main causes of cancer-related death worldwide, especially in women aged between 35 and 75 ...subtypes, triple ... See full document

... Ideally, new trials should be performed in this specific population, and trials performed with the general breast cancer population should plan and report separately the results for TNBC ... See full document

... expressing cancer cells by internalizing and trafficking to the lyso- some ...most breast cancers and promotes metastases by mediating intercellular adhe- sion, promoting tissue repair, regulating cell ... See full document

... advanced breast cancer were assigned to two sequential cohorts in a phase 2 ...BRCA-deficient breast cancers and show a favorable therapeutic index for a novel targeted treatment strategy in ... See full document

... The impact of valrubicin and lapatinib on the viability of normal and cancer cells was estimated using the cell counting kit-8 (CCK-8; Dojindo Molecular Technologies, Gathesburg, MD, USA). H9C2 and MDA-MB-231 ... See full document

... sensitive cancer early detection is highly desirable, because biological tissues show very low absorption and autofluorescence in the NIR spectrum window ...for cancer imaging has rapidly increased in ... See full document

... high-grade breast carcinomas, as ...are negative for the standard breast cancer markers and cannot be treated by established therapies such as endocrine and anti-HER2 ... See full document

... developing new targeted therapies for this pathway ...metastatic breast cancer (MBC) patients in order to evaluate Erdafitinib, which is an orally administered FGFR inhibitor, in ... See full document

... of therapies have been developed to date for specifi c molecular targets used as monotherapy or combined with traditional ...ing new markers expressed in basaloid and TN tumors will allow for the use of ... See full document

... Abstract: Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast ...specific targeted agents approved to treat ...Therefore, new ... See full document

... Abstract: Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease ...of breast cancer, directing the development of ... See full document

... The VAV family serves as a guanine nucleotide exchange factor (GEF) for the Rho family of GTPases [20]. VAV proteins contain protein subdomains, including an NH 2 -terminal calponin homology (CH) domain, an acidic domain ... See full document

... on cancer,” cancer remains one of the major causes of human morbidity and ...A new paradigm of targeted therapies holds the most promise for the future, making identification of ... See full document

... Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3–5 years but drops sharply ... See full document